智通财经APP获悉，高盛发布研报称，将基石药业-B(02616)评级从“中性”上调至“买入”，基于风险调整后的现金流折现法给出12个月目标价6.25港元，隐含20%上行空间。
高盛在其最新的中国医疗健康行业报告中指出ADC/双抗是中国的主要差异化优势(占对外授权交易的三分之一)。并提及基石药业管线2.0两大核心资产CS5001(ROR1 ADC)与CS2009(PD-1/VEGF/CTLA-4三特异性抗体/TsAb)，并看好两大核心产品的差异化优势与对外授权交易可视度。
该行将2026-2027年每股收益(EPS)预测从人民币-0.05/-0.04元调整至0.70/0.09元，反映预计CS2009在2026年达成对外授权交易。预计sugemalimab单抗2025年下半年起将在欧盟市场销售，截至2029年总销售收入2亿美元，扣除出厂成本公司将获得50%总销售收入，鉴于管线2.0出海能见度提升，该行将永续增长率从1%上调至2%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.